Administrative, drug costs drive US health spending far above other nations

A study published in JAMA found the U.S. pays roughly twice as much for healthcare than other high-income countries, despite similar utilization rates.

By Les Masterson • March 13, 2018

Drug spending growth to come solely from specialty meds, report says

Developed markets will shell out more than $300 billion for the often complex, expensive treatments this year, according to new estimates from IQVIA.

By Jacob Bell • March 13, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

GSK dodges another Advair copy as FDA reaffirms Hikma rejection

Hikma challenged a CRL and lost. Now, the company needs to conduct a new clinical study if it wants a shot at approval for its copycat.

By Jacob Bell • March 12, 2018

Gottlieb takes aim at payers, pharmas for blocking biosimilars

The FDA chief lambasted PBMs, insurers and branded drugmakers for allegedly blocking market entry of the copycat biologics.

By Lisa LaMotta , David Lim • March 8, 2018

For Cosentyx, Taltz, Siliq: A marketing race to differentiate

The IL-17 arena is getting pretty crowded, pushing drugmakers to explore various routes to market dominance.

By Jacob Bell • March 7, 2018

Teva tries rebranding in North America

The Israeli company is looking to change its image amid multiple challenges.

By Lisa LaMotta • March 7, 2018

Pharma taking liberties with DTC ads, says study

A new study analyzes current DTC ad campaigns and dissects whether disclosure of beneficial side effects could be misleading or interpreted as off-label promotion.

By Randi Hernandez • March 7, 2018

23andMe's DTC cancer test tentatively OK'd by FDA

Take-home genetic tests have gained traction with consumers, but regulators are warning they're no substitute for screenings at the doctor's office.

By Jacob Bell • March 7, 2018

UnitedHealthcare to use rebates to lower drug costs for patients

The major insurer plans to begin routing savings from drugmaker rebates directly to some consumers in a bid to lower out-of-pocket costs for prescription medicines.

By Ned Pagliarulo • March 6, 2018

Benzo overprescribing risk may be overlooked amid opioid crisis

A new commentary in the New England Journal of Medicine argues for greater monitoring and physician education around benzodiazepine use.

By Ned Pagliarulo • Feb. 28, 2018

Collegium warned for opioid drug marketing

The company was hit with a warning letter from the FDA after failing to prominently disclose the risks of the drug at a recent conference. 

By Jacob Bell • Feb. 28, 2018

PhRMA pitches value-based care, skeptics raise flags

Drugmakers have touted value-based contracting as a solution to rising prescription drug costs. But the connection isn't always straightforward.

By Randi Hernandez • Feb. 27, 2018

Hemlibra headed for Europe, eyes wider market

Some peg $5 billion in peak sales for Roche's new hemophilia drug, but that's only if it wins new indications in the U.S. and Europe.

By Jacob Bell • Feb. 27, 2018

Rubraca struggling from behind in PARP market

Clovis has battled to stay relevant in a competitive market that includes rival drugs from AstraZeneca and Tesaro.

By Lisa LaMotta • Feb. 27, 2018

Avonex's freefall still likely amid patent case loss

Newer treatments have lowered sales of the Biogen multiple sclerosis drug, and analysts expect that to continue regardless of the '755 patent.

By Jacob Bell • Feb. 26, 2018

EU turns down Puma breast cancer drug

The CHMP gave a negative opinion on Puma's Nerlynx, indicating efficacy might be an issue.

By Lisa LaMotta • Feb. 26, 2018

KemPharm nabs opioid approval, but no abuse-deterrent label

After several setbacks, the specialty pharma got a green light from the FDA, but not the broad label it wanted.

By Lisa LaMotta • Feb. 26, 2018

HIV patients claim CVS steered beneficiaries to its pharmacies

A class-action lawsuit raises questions about how CVS would act if the pharmacy chain successfully merges with Aetna.

By David Lim • Feb. 22, 2018

Spark lays groundwork for US Luxturna launch

The biotech is preparing to commercialize the first stateside gene therapy.

By Lisa LaMotta • Feb. 21, 2018

Gilead wins reprieve in Merck's $2.5B patent lawsuit

A federal judge ruled against Merck's patent for hepatitis C treatment. While the big pharma plans to appeal, it's a noteworthy win for Gilead in the meantime.

By Jacob Bell • Feb. 21, 2018

Mylan touts affordability for developing world HIV combo

Under the shadow of the EpiPen pricing saga, Mylan highlighted its credentials as an affordable provider of anti-retrovirals.

By Suzanne Elvidge • Feb. 21, 2018

Express Scripts joins Walgreens Boots to cut biosimilar costs

The pharmacy benefit manager is expanding its agreement with the drug store giant to simplify the supply chain for specialty pharmaceuticals.

By Lisa LaMotta • Feb. 21, 2018

Amazon selling private-label medications

The e-commerce company is offering an exclusive line of over-the-counter medications, thanks to healthcare supplier Perrigo.

By Daphne Howland • Feb. 21, 2018

Apricus plummets after ED drug rejection

Already approved in Europe, Vitaros didn't gain favor with U.S. regulators, who found CMC and safety issues with the erectile dysfunction drug.

By Jacob Bell • Feb. 16, 2018

J&J gets first-of-its-kind prostate cancer approval

The FDA greenlighted apalutamide for non-metastatic CRPC based on a new endpoint: metastasis-free survival. 

By Lisa LaMotta • Feb. 14, 2018